Shares of Precigen Inc. (PGEN) have been on a tear since last August, fueled by a regulatory breakthrough for its lead drug, PAPZIMEOS.
On Aug.15, 2025, PAPZIMEOS received full approval from the FDA for the treatment of adults with recurrent respiratory papillomatosis (RRP). Although its Biologics License Application was under review via the accelerated approval pathway, the agency granted full approval - thereby eliminating the need for a confirmatory clinical trial.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.